Sunshine Guojian Holds 2026 Interim Results Briefing
Sunshine Guojian Pharmaceutical held its 2026 interim results briefing, where management discussed the company's first-half financial performance and answered investor questions. The session covered operational highlights and strategic priorities for the remainder of the year.
Sunshine Guojian Pharmaceutical convened its 2026 interim results briefing, providing shareholders and analysts with an overview of the company's financial and operational performance for the first half of the year. During the session, management addressed key business developments and responded to investor inquiries regarding the company's outlook and strategic direction.